Risk Modification of Colorectal Adenoma byCYP7A1Polymorphisms and the Role of Bile Acid Metabolism in Carcinogenesis
Open Access
- 1 February 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 5 (2) , 197-204
Abstract
Cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in the conversion of cholesterol to bile acids, is a postulated gene modifier of colorectal cancer risk and target for the therapeutic bile acid, ursodeoxycholic acid (UDCA). We investigated associations between CYP7A1 polymorphisms and fecal bile acids, colorectal adenoma (CRA), and UDCA efficacy for CRA prevention. Seven tagging, single-nucleotide polymorphisms (SNP) in CYP7A1 were measured in 703 (355 UDCA, 348 placebo) participants of a phase III chemoprevention trial, of which 495 had known baseline fecal bile acid concentrations. In the placebo arm, participants with two minor Grs8192871 alleles (tag for a low activity promoter polymorphism at −204) had lower odds of high secondary bile acids (OR = 0.26, 95% CI: 0.10–0.69), and CRA at 3 years' follow-up (OR = 0.41, 95% CI: 0.19–0.89), than AA carriers. Haplotype construction from the six polymorphic SNPs showed participants with the third most common haplotype (Crs10957057Crs8192879Grs8192877Trs11786580Ars8192871Grs13251096) had higher odds of high primary bile acids (OR = 2.34, 95% CI: 1.12–4.89) and CRA (OR = 1.89, 95% CI: 1.00–3.57) than those with the most common CTACAG haplotype. Furthermore, three SNPs (rs8192877, rs8192871, and rs13251096) each modified UDCA efficacy for CRA prevention, and CCGTAG-haplotype carriers experienced 71% lower odds of CRA recurrence with UDCA treatment, an effect not present for other haplotypes (test for UDCA–haplotype interaction, P = 0.020). Our findings support CYP7A1 polymorphisms as determinants of fecal bile acids and risk factors for CRA. Furthermore, UDCA efficacy for CRA prevention may be modified by genetic variation in CYP7A1, limiting treatment benefit to a subgroup of the population. Cancer Prev Res; 5(2); 197–204. ©2011 AACR.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Common Variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4 , and CYP7A1 Genes as Predictors of Lipid-Lowering Response to Atorvastatin TherapyDNA and Cell Biology, 2010
- Ornithine Decarboxylase-1 Polymorphism, Chemoprevention With Eflornithine and Sulindac, and Outcomes Among Colorectal Adenoma PatientsJNCI: Journal of the National Cancer Institute, 2010
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- A Large Prospective Study of SEP15 Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and SurvivalCancer Prevention Research, 2010
- The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the populationAtherosclerosis, 2010
- Association between Fecal Bile Acids and Colorectal Cancer: A Meta-analysis of Observational StudiesYonsei Medical Journal, 2008
- Genetic polymorphism of cholesterol 7α‐hydroxylase (CYP7A1) and colorectal adenomas: Self Defense Forces Health StudyCancer Science, 2006
- Genetic Polymorphisms of Flavin Monooxygenase 3 in Sulindac-Induced Regression of Colorectal Adenomas in Familial Adenomatous PolyposisCancer Epidemiology, Biomarkers & Prevention, 2005
- A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype DataThe American Journal of Human Genetics, 2003
- Fecal constituents of a high-risk North American and a low-risk finnish population for the development of large bowel cancerCancer Letters, 1978